ReviewBlood2017
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
15 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph
Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 15 registered trials, which are not on this map. Cited by 3,221 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3,221citing papers in PubMed, 3 pooled it
265.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
NCT03821519 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation
Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation
NCT04090736 phase3active not recruitingnot on this mapstarted 2019, after this paper: background citation
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
A Phase II, Multicentre, Open Label Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Developing a Molecular Diagnostic Platform for Personalized Medicine for Acute Myeloid Leukemia
Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT04687761 phase1 / phase2completednot on this mapstarted 2020, after this paper: background citation
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than 60 Years Old Ineligible for Standard Induction Chemotherapy
Prognostic Value of CD318 in Acute Myeloid Leukemia Patients at Assiut University Hospital
Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly
A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LP-108, a BCL-2 Inhibitor, Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT06199557 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation
A Phase 1/2 Multicenter Open-label Study to Investigate Treatment of Hydroxyurea in Combination With Valproic Acid (VPA), or 6- Mercaptopurine in Combination With VPA in Patients With AML or HR-MDS Unfit for Standard Therapy
NCT07060001 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Who cites it
3,221 citing papers in PubMed, 3 syntheses or guidelines pooled it, 5,802 citations in OpenAlex.
- Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review.Annals of medicine · 2026Pooled it
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.Blood advances · 2026Trial
- Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.NEJM evidence · 2026Trial
- A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.Bone marrow transplantation · 2026Trial
- Trial
- Trial
- Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.Blood cancer discovery · 2026Trial
- Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.Blood neoplasia · 2026Trial
- Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.Blood neoplasia · 2026Trial
- Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia.Blood neoplasia · 2026Trial
- CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.Nature medicine · 2026Trial
- CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.Blood advances · 2026Trial
- Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.Journal of hematology & oncology · 2026Trial
- Quizartinib for Newly DiagnosedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Trial
- Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.European journal of clinical pharmacology · 2025Trial
- Cancer Survival at a Comprehensive Cancer Center Compared With Surveillance, Epidemiology, and End Results (SEER) Estimates.American journal of medicine open · 2026Article
- Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes.Annals of medicine · 2026Article
3,161 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 19 institutions in 10 countries.
Hartmut DöhnerDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.
Elihu EsteyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
David GrimwadeDepartment of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Sergio AmadoriDepartment of Biomedicine and Prevention, Università di Roma "Tor Vergata," Rome, Italy.
Frederick R AppelbaumClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Thomas BüchnerDepartment of Hematology/Oncology, University of Münster, Münster, Germany.
Hervé DombretInstitut Universitaire d'Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Benjamin L EbertDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Pierre FenauxService d'Hématologie, Hôpital Saint-Louis, Paris, France.
Richard A LarsonDepartment of Medicine, University of Chicago, Chicago, IL.
Ross L LevineLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Francesco Lo-CocoDepartment of Biomedicine and Prevention, Università di Roma "Tor Vergata," Rome, Italy.
Tomoki NaoeNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Dietger NiederwieserDepartment of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany.
Gert J OssenkoppeleDepartment of Haematology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands.
Miguel SanzDepartment of Hematology, University Hospital La Fe, University of Valencia, Valencia, Spain.
Jorge SierraHematology Department, Hospital de la Santa Creu i Sant Pau, Jose Carreras Leukemia Research Institute, Barcelona, Spain.
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Andrew H WeiDepartment of Clinical Hematology, The Alfred Hospital, Melbourne, Australia.
Bob LöwenbergDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Fred Hutch Cancer Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Rome Tor Vergata · ITAssistance Publique – Hôpitaux de Paris · FRBrigham and Women's Hospital · USErasmus MC · NLHôpital Saint-Louis · FRHospital Universitari i Politècnic La Fe · ESJosep Carreras Leukaemia Research Institute · ESKing's College London · GBLeipzig University · DEMonash University · AUNational Hospital Organization · JPNational Taiwan University Hospital · TWThe Ohio State University · USUniversität Ulm · DEUniversity of Chicago · USUniversity of Münster · DEVrije Universiteit Amsterdam · NL
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MNCI NIH HHS P30 CA016058NCI NIH HHS U10 CA180861
Abstract
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Indexed as
Disease ManagementHematopoietic Stem Cell TransplantationAdultAntineoplastic AgentsConsensusDrug Administration ScheduleGenetic TestingHumansImmunophenotypingInternational CooperationLeukemia, Myeloid, AcuteNeoplasm, ResidualPractice Guidelines as TopicRisk FactorsTransplantation, AutologousTreatment OutcomeAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02488408ClinicalTrials.gov
NCT03821519ClinicalTrials.gov
NCT04090736ClinicalTrials.gov
NCT04230239ClinicalTrials.gov
NCT04310592ClinicalTrials.gov
NCT04446741ClinicalTrials.gov
and 9 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.